Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase EARLY_PHASE1 1

Status

Completed 20Terminated 4Withdrawn 3Unknown 2Suspended 1No longer available 1Active not recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3Sarcoma 1Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Breast Neoplasms 28Carcinoma, Non-Small-Cell Lung 20Triple Negative Breast Neoplasms 9Ovarian Neoplasms 8Lung Neoplasms 8Uterine Cervical Neoplasms 6Adenocarcinoma of Lung 6Neoplasms 5Neoplasm Metastasis 5Esophageal Neoplasms 5Carcinoma, Ovarian Epithelial 4Stomach Neoplasms 3Recurrence 3Prostatic Neoplasms 3Esophageal Squamous Cell Carcinoma 3Urinary Bladder Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Platinum-Refractory Fallopian Tube Carcinoma 2Pancreatic Neoplasms 2Head and Neck Neoplasms 2Fallopian Tube Neoplasms 2Adenocarcinoma, Bronchiolo-Alveolar 2Unspecified Adult Solid Tumor, Protocol Specific 1Thyroid Neoplasms 1Thyroid Carcinoma, Anaplastic 1Solid Tumors 1Small Cell Lung Carcinoma 1Sarcoma 1Recurrent High Grade Uterine Cancer 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1

Interventions

Docetaxel 11Prednisone 10Leuprolide 10Magnetic Resonance Spectroscopy 9bicalutamide 8Radiotherapy 7Abiraterone Acetate 7Biopsy 6gallium 68 PSMA-11 5acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 5Surveys and Questionnaires 5Metformin 5Goserelin 5radium Ra 223 dichloride 4enzalutamide 4apalutamide 4Specimen Handling 4Injections 4Androgen Antagonists 4pembrolizumab 3orteronel 3cabazitaxel 3abiraterone 3Radiotherapy, Intensity-Modulated 3Radiosurgery 3Pioglitazone 3Paclitaxel 3Exercise 3Brachytherapy 3Blood Specimen Collection 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Withdrawn × Prostatic Neoplasms × Paclitaxel × Clear all
NCT05238831 2024-01-23

SMMART Adaptive Clinical Treatment (ACT) Trial

OHSU Knight Cancer Institute

Phase EARLY_PHASE1 Withdrawn
BreastGastrointestinalGenitourinaryGynecologicSarcoma

Breast Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma

NCT00003622 2017-07-13

Vinorelbine Plus Paclitaxel in Treating Patients With Metastatic Prostate Cancer That Is Refractory to Hormone Therapy

George Washington University

Phase 2 Withdrawn
Genitourinary

Prostatic Neoplasms

NCT00084565 2013-07-10

Paclitaxel, Topotecan, and Estramustine in Treating Patients With Metastatic Hormone-Refractory Prostate Cancer

Fox Chase Cancer Center

Phase 2 Withdrawn
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡